^
    Back
    Association details:
    Biomarker:MET mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Crizotinib for ROS1 and MET Activated Lung Cancer

    Excerpt:
    ......
    Trial ID:
    NCT04084717
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

    Excerpt:
    ......
    Trial ID:
    NCT03088930
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

    Excerpt:
    ......
    Trial ID:
    METROS
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Target Oncol
    Title:

    Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis

    Excerpt:
    Our study highlighted and confirmed the efficacy of crizotinib in patients with NSCLC with ROS1 or MET genetic alterations.
    DOI:
    10.1007/s11523-020-00745-7